Iodine Software
AI-driven clinical-documentation and revenue-cycle automation platform for US hospitals — acquired by Waystar in October 2025 for $1.25B from Advent International, Bain Capital Ventures and Silversmith Capital Partners. Historical entry preserved for category-creator credit; live successor inside Waystar’s healthcare-payments software stack.
The Business
Iodine Software was an Austin-based healthcare-AI company founded in 2010 by William Chan and Mike Kadyan. The company built an AI-and-ML-driven clinical documentation improvement (CDI) platform anchored on hospital EHR data, with the flagship AwareCDI product line and the Concurrent application that prioritised CDI specialists’ workload by identifying records most likely to contain documentation errors. The platform was designed to extend across the revenue-integrity surface inside US health systems and integrated into Epic and Cerner EHR workflows. Advent International led a November 2021 strategic growth investment that valued the company above $1B, with Bain Capital Ventures and Silversmith Capital Partners as continuing shareholders from their 2018 participation. Waystar Holding Corp (NASDAQ: WAY) announced its agreement to acquire Iodine Software on 22 July 2025 for $1.25B in enterprise value and closed the transaction on 1 October 2025 per the PR Newswire release. Iodine is preserved in the IM universe as a Wound-Down historical entry; the AwareCDI product line, the founding team’s product DNA and the strategic positioning all transitioned into Waystar’s healthcare-payments software stack.
Customers and Distribution
Iodine is a Wound-Down entry — the company no longer operates as a standalone entity. At the time of the October 2025 Waystar acquisition, Iodine served approximately 800 US hospitals and health systems per the Waystar press release, with deep integration into Epic and Cerner EHR workflows and a customer base concentrated in mid-size and large US health systems. Pre-acquisition revenue and ARR figures were not separately disclosed in primary sources. Post-acquisition, the Iodine customer base was folded into Waystar’s healthcare-payments software stack and the AwareCDI cross-sell motion targets Waystar’s existing footprint of 30,000+ provider organisations. The live customer count and revenue trajectory are tracked via Waystar’s quarterly disclosures rather than on this historical entry. This Iodine page is preserved for category-creator credit and continuity context, not for live commercial-trajectory tracking.
Model Strategy
Iodine’s historical model strategy was an early-mover Verticals-first play under the IM Framework eight-trajectories taxonomy applied to healthcare AI: the original strategic bet was that AI-driven clinical-documentation improvement combined with deep Epic/Cerner EHR integration could create a defensible category-leader position inside US hospital revenue-cycle management. The bet resolved successfully via the October 2025 Waystar acquisition at $1.25B enterprise value — Iodine became the worked example of an AI-CDI specialist absorbed into a public RCM platform to extend AI leadership across the healthcare-payments stack. Post-acquisition, the AwareCDI product line continues to operate as the AI-CDI surface inside Waystar, with the strategic bet now resolved into the Waystar AI-enabled-RCM thesis rather than Iodine as a standalone entity.
Leadership Team
Iodine is a Wound-Down entry — the company no longer exists as a standalone entity. The AwareCDI product line, the founding team’s product DNA and the strategic positioning all transitioned into Waystar’s healthcare-payments software stack via the October 2025 acquisition. Pre-acquisition Iodine had raised funding from Advent International (Series A growth investment, November 2021, $1B+ valuation) with Bain Capital Ventures and Silversmith Capital Partners as 2018-era shareholders.
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Oct 2025 | Acquisition by Waystar (closed) | $1.25B enterprise value | — | Waystar Holding Corp (NASDAQ: WAY) |
| Nov 2021 | Strategic growth investment | Undisclosed | $1B+ | Advent International (with Bain Capital Ventures, Silversmith Capital Partners as continuing shareholders) |
| 2018 | Growth round | Undisclosed | — | Bain Capital Ventures, Silversmith Capital Partners |
Waystar announced the agreement to acquire Iodine Software on 22 July 2025 in an all-cash-and-stock transaction valued at $1.25B enterprise value (50/50 cash and stock consideration per the PR Newswire release) and closed the transaction on 1 October 2025. Pre-acquisition Iodine had received strategic growth investment from Advent International in November 2021 at a $1B+ valuation, with Bain Capital Ventures and Silversmith Capital Partners remaining shareholders from their 2018 participation. Round-by-round pre-2021 capital figures are not separately disclosed in primary sources beyond the Advent 2021 milestone. Post-acquisition Iodine is internally funded as part of Waystar; Iodine-specific spend is not separately broken out.
Competitive Landscape
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Solventum Health Information Systems ((Solventum NYSE: SOLV)) |
AI-driven clinical-documentation-improvement platform spun out of 3M Health Care; the principal pure-play CDI competitor to Iodine’s AwareCDI at the October 2025 acquisition moment. | Sold direct into US health-system CFO and revenue-integrity buyers; carried the 3M Health Information Systems installed base across acute-care hospitals. | High historical — the 3M Health Information Systems CDI platform (now Solventum following the 3M Health Care spin) was the principal head-to-head with Iodine on AI-driven clinical documentation improvement; remains the live competitor against the Iodine-inside-Waystar continuation. |
| Nuance DAX / Microsoft ((NASDAQ: MSFT)) |
Ambient clinical-documentation (DAX Copilot) plus Dragon medical-NLP under Microsoft since the April 2022 acquisition close; flanking surface adjacent to CDI rather than direct head-to-head. | Microsoft enterprise healthcare channel plus the legacy Nuance Dragon footprint inside US health systems; Epic and Cerner integration partnerships. | Medium-high historical — Nuance Dragon and DAX Copilot (now part of Microsoft following the April 2022 close) competed on adjacent ambient-documentation and clinical-NLP layers; less direct on CDI but a credible flanking surface. |
| Epic Systems — native CDI tooling | Native CDI and revenue-integrity tooling shipped inside the Epic EHR; positioned as the in-platform default rather than a best-of-breed AI layer. | Inside every Epic deployment by default; bundled into enterprise EHR contracts and the principal substitution risk on the in-EHR-native CDI trajectory. | High historical — Epic’s native CDI and revenue-integrity tooling competed on the same hospital procurement layer; the Epic platform is the principal EHR Iodine integrated with and the largest substitution risk on the in-EHR-native trajectory. |
| Optum / UnitedHealth ((NYSE: UNH)) |
UnitedHealth-owned revenue-cycle and clinical-analytics platform; competes on adjacent RCM surfaces rather than the pure AI-CDI lane. | Captive distribution into UnitedHealth-affiliated providers plus a direct US health-system salesforce; payer-provider integration is the channel narrative. | Medium historical — the Optum revenue-cycle and clinical-analytics platforms competed on adjacent RCM surfaces; complementary in many hospital deployments but a structural competitor on the integrated-payer-provider thesis. |
| AGS Health | Pure-play RCM-and-CDI services and technology vendor; smaller AI-CDI footprint than Iodine but credible on the mid-market hospital segment. | Mid-market US health-system direct sales plus services-led BPO contracts; lighter EHR-native integration depth than Iodine had on Epic and Cerner. | Medium historical — pure-play RCM-and-CDI services and technology competitor; smaller AI-CDI footprint than Iodine but credible on the mid-market hospital procurement segment. |
Potential Risks
Historical entry — Iodine no longer exists as a standalone company
Iodine Software was acquired by Waystar on 1 October 2025 for $1.25B enterprise value and integrated into the Waystar AI-enabled healthcare-payments software stack. This Iodine page is preserved for category-creator credit and historical context only. The active surface for tracking the AwareCDI product trajectory is Waystar’s quarterly earnings calls and investor-day disclosures.
Founder-team transition risk through the integration
Co-founders William Chan and Mike Kadyan continued in senior roles through the Advent International recapitalisation in November 2021 and the Waystar acquisition close in October 2025. Departures of the broader Iodine bench since acquisition do not appear to have destabilised the product. Continued bench-and-founder retention through 2026 is tracked via Waystar’s disclosures rather than on this historical entry.
Strategic-bet resolution
The original Iodine strategic bet — that AI-driven clinical-documentation improvement could create a defensible category-leader position inside US healthcare revenue-cycle management — resolved successfully via the October 2025 Waystar acquisition at $1.25B enterprise value. Future trajectory questions (CMS coding-rule cycles, EHR-native CDI substitution, generative-AI ambient-documentation flanking) apply to the Iodine-inside-Waystar continuation rather than to Iodine as a standalone entity.
Cross-reference discipline
Visitors looking for the live healthcare-AI scoring relevant to the Iodine-originated product line should consult Waystar’s quarterly disclosures and the Healthcare AI Category Report when published. Iodine is not actively re-scored on future v1.6ep evidence-pass cycles.
Historical-entry preservation rationale
Iodine is preserved in the universe because category-creator credit on AI-driven clinical documentation improvement and the worked example of healthcare-AI-tuck-in-into-public-RCM-platform both have lasting analytical value. The entry is not actively re-scored on future v1.6ep evidence-pass cycles; the next refresh will track only the live successor product inside Waystar.
Recent IM Coverage
- Healthcare AI — sector landing May 2026.
- IM Framework Methodology May 2026.
Show recent press coverage of Iodine Software
- Jul 2025 — Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments (PR Newswire / Waystar)
- Jul 2025 — Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments (Waystar Investor Relations)
- Jul 2025 — Waystar finalizes $1.25B acquisition of Iodine Software to boost AI-enabled revenue cycle management (Fierce Healthcare)
- Oct 2025 — Waystar Closes Acquisition of Iodine Software, Extending AI Leadership in Healthcare Software (PR Newswire / Waystar)
- Dec 2021 — Iodine Software Surpasses $1 Billion Valuation With Strategic Growth Investment from Advent International (BusinessWire)
- Dec 2021 — Iodine Software Surpasses $1 Billion Valuation With Strategic Growth Investment from Advent International (Iodine Software Newsroom)
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Iodine is a Wound-Down entry — the company no longer exists as a standalone entity. Pre-acquisition revenue and ARR figures were not disclosed in primary sources at the time of the October 2025 Waystar acquisition. Post-acquisition Iodine revenue is reported as part of Waystar’s healthcare-payments segment; consult Waystar’s quarterly disclosures for the live trajectory.
- Customer accounts (at acquisition): Iodine served approximately 800 US hospitals and health systems at the time of the October 2025 Waystar acquisition per the Waystar acquisition press release. Post-acquisition customer count for the AwareCDI continuation is tracked via Waystar’s disclosures.
- Headcount (at acquisition): Iodine did not separately disclose precise headcount at acquisition; Austin-headquartered with engineering, clinical and customer-success teams. Post-acquisition headcount is folded into Waystar’s operating base and is not separately broken out.
- Funding to date (at acquisition): Waystar acquired Iodine Software for $1.25B enterprise value on 1 October 2025 per the closing press release. Pre-acquisition Iodine received strategic growth investment from Advent International in November 2021 at a $1B+ valuation, with Bain Capital Ventures and Silversmith Capital Partners as continuing shareholders from 2018.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
